// App-Quantinova.ai

P1351 : CHARACTERIZING ALLOGENEIC STEM CELL TRANSPLANTATION SAFETY IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES AFTER PEMBROLIZUMAB THERAPY

Researchers

Presenter

  • John Kuruvilla

Principal Investigators

  • Philippe Armand

  • Alex F. Herrera

  • Vincent Ribrag

  • Pauline Brice

  • Catherine Thieblemont

  • Bastian Von Tresckow

  • Eunhee Kim

  • Patricia Marinello

  • Samhita Chakraborty

  • Robert Orlowski

  • Pier Luigi Zinzani

Medical Centers

  • Institut Gustave Roussy,Villejuif,Франция

  • University Hospital Cologne, University of Cologne, and West German Cancer Center, Essen

  • Princess Margaret Cancer Center, Toronto, ON, Canada

  • City of Hope Cancer Center,Duarte,Verenigde Staten

  • Co., Inc.,Kenilworth,United States

  • APHP, Hôpital Saint-Louis, Hémato-oncologie, Université de Paris, Paris Diderot, Paris, France

  • Institut Gustave-Roussy, Villejuif, France

  • Institut Gustave-Roussy, Villejuif, France

  • Merck &amp

  • APHP, Hôpital Saint-Louis, Hemato-Oncologie, Université de Paris,Paris,Frankreich

  • Cit

  • City of Hope National Medical Center,Duarte,États-unis

  • Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA

  • Institut Gustave-Roussy, Villejuif, France

  • APHP

  • Co., Inc.,Kenilworth,Vereinigte Staaten

  • Co., Inc, Kenilworth, NJ

  • Princess Margaret Cancer Centre,Toronto,Канада

  • Dana–Farber Cancer Institute, Harvard Medical School, Boston, MA, United States

  • Co., Inc.,Kenilworth,Vereinigte Staaten

  • Institut Gustave-Roussy, Villejuif, France

  • City of Hope Cancer Center,Duarte,Verenigde Staten

  • Co., Inc.,Kenilworth, NJ,États-unis

  • Princess Margaret Cancer Center, Toronto, ON, Canada

  • IRCCS Azienda Ospedaliero‐Universitaria di Bologna, Istituto di Ematologia 'Seràgnoli', Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna,Bologna,Italia

  • Princess Margaret Cancer Center, Toronto, ON, Canada

  • University Hospital Cologne, University of Cologne, and West German Cancer Center, Essen University Hospital, University of Duisburg-Essen,Essen,Allemagne

  • IRCCS Azienda Ospedaliero‐Universitaria di Bologna, Istituto di Ematologia 'Seràgnoli', Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna,Bologna,Italia

  • IRCCS Azi

  • City of Hope Medical Center,Duarte,Stati Uniti

  • Dana–Farber Cancer Institute, Harvard Medical School, Boston, MA, United States

  • Institut Gustave-Roussy, Villejuif, France

  • APHP, Hôpital Saint-Louis, Hemato-Oncologie, Université de Paris,Paris,Frankreich

  • Dana-Farber Cancer Institute, Harvard Medical School,Boston,Estados Unidos

  • Co., Inc.,Kenilworth,Stati Uniti

  • Princess Margaret Cancer Centre,...

  • Dana-Farber Cancer Institute, Harvard Medical School,Boston,Estados Unidos

  • Institut Gustave-Roussy, Villejuif, France

  • City of Hope National Medical Center, Duarte, United States,

  • Co., Inc.,Kenilworth,Estados Unidos

  • Dana Farber Cancer Institute, MA

  • University Hospital Cologne, University of Cologne, and West German Cancer Center, Essen University Hospital, University of Duisburg-Essen,Essen,Allemagne

  • City of Hope Cancer Center,Duarte,Stati Uniti

Locations

  • Canada

  • United States

  • France

  • Germany

  • United Kingdom

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Oncology (ONC)

Disease

  • Graft-versus-host disease

  • Hematological malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Pembrolizumab

  • Allopurinol

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I

Study Id's

  • NCT01953692

  • NCT02453594

  • NCT02576990

  • NCT02684292

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved